The FDA is reviewing the supplemental NDA for cabozantinib ... The Company is seeking approval for acute treatment of migraine with or without aura.

The FDA is reviewing the application for bentracimab for use as a ticagrelor reversal agent in patients with uncontrolled bleeding or in those who require urgent surgery or invasive procedure.

It noted at the time more countries would get access as regulators approved the feature, and the FDA was apparently the first to come through outside of Europe, boosting support to 15 countries.

Royalty-free licenses let you pay once to use copyrighted images and video clips in personal and commercial projects on an ongoing basis without requiring additional payments each time you use that ...

Donald Trump says Ukraine's President Zelensky will sign a "very big agreement" in the US on Friday Kyiv and Washington have been discussing a deal to share Ukraine's mineral wealth in return for ...

Figure 1: FDA approvals by year, 2015-2024. Credit: GlobalData. The US Food and Drug Administration (FDA) approved 126 innovator and biosimilar drugs in 2024, significantly lower than the 149 ...

The OFA additionally argued that even producers of FDA-approved semaglutide revealed in a recent SEC filing that the “supply constraints’ and ‘drug shortage notifications’ will continue into the ...

Aliyev is expected to sign final agreements for investment during ... Prior to the trip, Pakistan’s Economic Coordination Committee approved a three-year extension of the LNG Framework Agreement ...

Compounders are on alert after the US Food and Drug Administration (FDA) declared the shortage of semaglutide –the active ingredient in glucagon-like peptide 1 receptor agonist (GLP-1RA) Wegovy ...

FDA-approved drugs can be compounded under certain conditions such as if the original approved drug is in shortage and unavailable. With Novo’s two flagship products removed from the shortage list, ...

This also places ingredient safety regulations under the FDA's authority ... same rigor as additives that go through the pre-market approval process.

Sotagliflozin, an FDA-approved drug for type 2 diabetes and kidney disease, significantly reduces heart attack and stroke risk, according to an international trial. Unlike other SGLT2 inhibitors, it ...